SCHEMBL3301450

SCHEMBL3301450

NCC1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.54
MAPT P10636 4/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPK1 P28482 2/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
GFER P55789 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
HRH3 Q9Y5N1 1/20 0.52
NOTUM Q6P988 1/20 0.46
KDM4E B2RXH2 2/20 0.44
TP53 P04637 2/20 0.44
DEGS1 O15121 1/20 0.44
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
RAB9A P51151 1/20 0.42
CASP7 P55210 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15651158 0.83 MAPT (0.52) BPTFMAPTALDH1A1MAPK1LMNA
SCHEMBL344787 0.82 HRH3 (0.47) BPTFMAPTALDH1A1MAPK1LMNA
SCHEMBL13182959 0.81 ADRB1 (0.48) BPTFMAPTNPC1RAB9ANPSR1
SCHEMBL12505446 0.81 HTR3E (0.48) BPTFMAPTALDH1A1MAPK1LMNA
SCHEMBL16394309 0.81 SLC6A2 (0.49) BPTFMAPT
SCHEMBL3303532 0.81 HRH3 (0.52) MAPTALDH1A1MAPK1LMNAHTT
SCHEMBL718248 0.81 BPTF (0.53) BPTFLMNAHRH3NOTUM
SCHEMBL1735105 0.81 HRH4 (0.56) BPTFHRH3NOTUMDEGS1
SCHEMBL8133600 0.79 HRH3 (0.50) MAPTALDH1A1MAPK1LMNAHTT
SCHEMBL377434 0.79 ALDH1A1 (0.59) MAPTALDH1A1MAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019179362-A1 AMIDINE AND GUANIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF 四川科伦博泰生物医药股份有限公司 2019-09-26 WO disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
CN-101605783-A Novel N, N' -2, 4-dianilinopyrimidine derivatives as drugs, pharmaceutical compositions, especially as IKK inhibitors, and preparation thereof SANOFI AVENTIS (FR) 2009-12-16 CN disclosed
EP-2118092-A1 NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS Sanofi-Aventis (FR) 2009-11-18 EP disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
WO-2008099073-A1 N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF SANOFI-AVENTIS (FR) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE BPTF 1064/4885MAPT 3372/4885ALDH1A1 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.